JCB logo
R&D Systems: Proteome Profiler 96
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online 28 January 2002. doi:10.1083/jcb.200110119
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 557K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, Y.
Right arrow Articles by LeBlanc, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, Y.
Right arrow Articles by LeBlanc, A.
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

© The Rockefeller University Press, 0021-9525/2002/2/519 $5.00
The Journal of Cell Biology, Volume 156, Number 3, February 4, 2002 519-529

Article

Selective cytotoxicity of intracellular amyloid ß peptide1–42 through p53 and Bax in cultured primary human neurons



Yan Zhang1,4, Richard McLaughlin3, Cynthia Goodyer2 and Andréa LeBlanc1,4

1 Department of Neurology and Neurosurgery, McGill University, Montréal, Québec H3A 2T5, Canada
2 Department of Pediatrics, McGill University, Montréal, Québec H3A 2T5, Canada
3 Neurochem, Inc., Ville Saint-Laurent, Québec H4S 2A1, Canada
4 The Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec H3T 1E2, Canada

Address correspondence to Andréa LeBlanc, The Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, The Sir Mortimer B. Davis Jewish General Hospital, 3755 Côte Ste-Catherine Rd., Montréal, Québec H3T 1E2, Canada. Tel.: (514) 340-8260 Fax: (514) 340-8295. E-mail: andrea.leblanc{at}mcgill.ca

Extracellular amyloid ß peptides (Aßs) have long been thought to be a primary cause of Alzheimer's disease (AD). Now, detection of intracellular neuronal Aß1–42 accumulation before extracellular Aß deposits questions the relevance of intracellular peptides in AD. In the present study, we directly address whether intracellular Aß is toxic to human neurons. Microinjections of Aß1–42 peptide or a cDNA-expressing cytosolic Aß1–42 rapidly induces cell death of primary human neurons. In contrast, Aß1–40, Aß40–1, or Aß42–1 peptides, and cDNAs expressing cytosolic Aß1–40 or secreted Aß1–42 and Aß1–40, are not toxic. As little as a 1-pM concentration or 1500 molecules/cell of Aß1–42 peptides is neurotoxic. The nonfibrillized and fibrillized Aß1–42 peptides are equally toxic. In contrast, Aß1–42 peptides are not toxic to human primary astrocytes, neuronal, and nonneuronal cell lines. Inhibition of de novo protein synthesis protects against Aß1–42 toxicity, indicating that programmed cell death is involved. Bcl-2, Bax-neutralizing antibodies, cDNA expression of a p53R273H dominant negative mutant, and caspase inhibitors prevent Aß1–42-mediated human neuronal cell death. Taken together, our data directly demonstrate that intracellular Aß1–42 is selectively cytotoxic to human neurons through the p53–Bax cell death pathway.

Key Words: Alzheimer's disease; amylois ß peptide; p53; Bax; neurotoxicity


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

With Aß, the danger lies within
William A. Wells
J. Cell Biol. 2002 156: 411. [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents